Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | ABCC1 | P33527 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5463743 | 0.77 | MAPT (0.77) | LMNAMAPTPOLBKCNH2ABCC1 | |
| SCHEMBL18924338 | 0.73 | HRH3 (0.70) | POLBHRH3KCNH2GAASMN1; SMN2 | |
| SCHEMBL5524600 | 0.72 | LMNA (0.62) | LMNAMAPTPOLBKCNH2ABCC1 | |
| SCHEMBL5530712 | 0.72 | LMNA (0.69) | LMNAMAPTPOLBABCC1GAA | |
| SCHEMBL5530713 | 0.72 | LMNA (0.69) | LMNAMAPTPOLBABCC1GAA | |
| SCHEMBL5526125 | 0.71 | NOTUM (0.50) | MAPTPOLBGAASMN1; SMN2KDM4E | |
| SCHEMBL7837578 | 0.70 | NOTUM (0.49) | LMNAMAPTPOLBHRH3GAA | |
| SCHEMBL13886219 | 0.70 | KDM4E (0.55) | LMNAMAPTPOLBGAASMN1; SMN2 | |
| SCHEMBL5523816 | 0.68 | LMNA (0.57) | LMNAMAPTPOLBKCNH2ABCC1 | |
| SCHEMBL5531540 | 0.68 | MAPT (0.67) | LMNAMAPTPOLBGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | LMNA 2932/4885MAPT 680/4885POLB 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.